PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16002050-6	2005	The presence of MK571, an MRP inhibitor, significantly enhanced (14)C-PEITC accumulation in MDCK II/MRP2 but not MDCK II/wt cells.	verlukast	16-21	ATP binding cassette subfamily C member 2	Canis lupus familiaris	100-104	
22430364-8	2012	The efflux ratios in MRP2 and Bcrp1 transfected cell lines were greatly decreased in the presence of MK-571 and Ko143, respectively, which indicated that forsythiaside efflux by MRP2 and Bcrp1 were significantly inhibited by their selective inhibitors.	verlukast	101-107	ATP binding cassette subfamily C member 2	Canis lupus familiaris	21-25	
22430364-8	2012	The efflux ratios in MRP2 and Bcrp1 transfected cell lines were greatly decreased in the presence of MK-571 and Ko143, respectively, which indicated that forsythiaside efflux by MRP2 and Bcrp1 were significantly inhibited by their selective inhibitors.	verlukast	101-107	ATP binding cassette subfamily C member 2	Canis lupus familiaris	178-182	
17543436-9	2007	This accumulation was decreased in LLCPK1-MDR1 and MDCKII-MRP2 cells, compared to wild-type cells, and the decrease could be reversed by valspodar or MK571.	verlukast	150-155	ATP binding cassette subfamily C member 2	Canis lupus familiaris	58-62	
17451894-3	2007	Lopinavir efflux was directional and was completely inhibited by MK-571, a selective MRP family inhibitor in the MDCKII-MRP2 cell line.	verlukast	65-71	ATP binding cassette subfamily C member 2	Canis lupus familiaris	120-124	
17451894-7	2007	The efflux ratios in MRP2 and MDR1 transfected cell lines were close to unity in the presence of MK-571 and P-gp-4008, respectively, indicating that LVR efflux by MRP2 and P-gp was completely inhibited by their selective inhibitors.	verlukast	97-103	ATP binding cassette subfamily C member 2	Canis lupus familiaris	21-25	
17451894-7	2007	The efflux ratios in MRP2 and MDR1 transfected cell lines were close to unity in the presence of MK-571 and P-gp-4008, respectively, indicating that LVR efflux by MRP2 and P-gp was completely inhibited by their selective inhibitors.	verlukast	97-103	ATP binding cassette subfamily C member 2	Canis lupus familiaris	163-167	
17481833-8	2007	This accumulation was significantly decreased in LLCPK1/MDR1 and MDCKII/MRP2 cells, compared to wild-type cells, and this effect was reversed by valspodar and MK571, respectively.	verlukast	159-164	ATP binding cassette subfamily C member 2	Canis lupus familiaris	72-76	
25844889-6	2015	RESULTS: Uptake studies showed a higher accumulation in the presence of inhibitors (GF120918 and ketoconazole for P-gp; MK571 for MRP2; and beta-estradiol for BCRP) as well as RX-10045.	verlukast	120-125	ATP binding cassette subfamily C member 2	Canis lupus familiaris	130-134	
18620036-10	2008	In the presence of MK-571, a MRP family inhibitor, there was a significant increase in the permeabilities of SQV and Gly-Val-SQV indicating that these compounds are probably substrates for MRP-2.	verlukast	19-25	ATP binding cassette subfamily C member 2	Canis lupus familiaris	189-194	
14511674-5	2003	Accumulation of EGCG and its methyl metabolites was also increased approximately 10-fold in the presence of MK-571 in MDCKII/MRP2 cells.	verlukast	108-114	ATP binding cassette subfamily C member 2	Canis lupus familiaris	125-129	
15451006-6	2004	This effect was seen when MK 571 (MRP1 and MRP2 inhibitor) or verapamil (MRP1 and MDR1 inhibitor) were used to block efflux protein activity.	verlukast	26-32	ATP binding cassette subfamily C member 2	Canis lupus familiaris	43-47	
15125776-12	2004	However, the decrease in the efflux ratio of CPT in MDCKII/MRP2 cells (2.31 to 1.03) suggests that CPT efflux was completely inhibited by MK571, a potent inhibitor of the Multidrug Resistance Protein transporter family.	verlukast	138-143	ATP binding cassette subfamily C member 2	Canis lupus familiaris	59-63	
14570756-10	2003	This conclusion was further strengthened when MK-571 increased the uptake by MRP2-MDCK cells as much as 3.6-fold (p < 0.01).	verlukast	46-52	ATP binding cassette subfamily C member 2	Canis lupus familiaris	77-81	
31006447-3	2019	Resulting data identified 8 flavonoids as MRP2 substrates based on their high CUMK with MK-571 in MDCK/MRP2 cells.	verlukast	88-94	ATP binding cassette subfamily C member 2	Canis lupus familiaris	42-46	
12054569-5	2002	In vitro, the cellular accumulation of B22956/1 was significantly lower in both MRP1 and MRP2 transfected cells as compared to wild type MDCKII cells, and the cellular efflux was prevented by the MRP inhibitor MK571, indicating the involvement of both MRP2 and MRP1 in the transport of B22956/1.	verlukast	210-215	ATP binding cassette subfamily C member 2	Canis lupus familiaris	89-93	
12054569-5	2002	In vitro, the cellular accumulation of B22956/1 was significantly lower in both MRP1 and MRP2 transfected cells as compared to wild type MDCKII cells, and the cellular efflux was prevented by the MRP inhibitor MK571, indicating the involvement of both MRP2 and MRP1 in the transport of B22956/1.	verlukast	210-215	ATP binding cassette subfamily C member 2	Canis lupus familiaris	252-256	
31006447-3	2019	Resulting data identified 8 flavonoids as MRP2 substrates based on their high CUMK with MK-571 in MDCK/MRP2 cells.	verlukast	88-94	ATP binding cassette subfamily C member 2	Canis lupus familiaris	103-107	
27535101-12	2017	Furthermore, the efflux of HDND-7 was apparently reduced in the presence of MRP2 inhibitors MK-571 or probenecid.	verlukast	92-98	ATP binding cassette subfamily C member 2	Canis lupus familiaris	76-80